NCT03512756 2024-11-06
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
Tyme, Inc
Phase 2/3 Terminated
Tyme, Inc
Ruijin Hospital
The Netherlands Cancer Institute
Merrimack Pharmaceuticals
European Organisation for Research and Treatment of Cancer - EORTC